Modality
mRNA
MOA
CD3xCD20
Target
GPRC5D
Pathway
STING
HNSCCFL
Development Pipeline
Preclinical
~Jan 2017
→ ~Apr 2018
Phase 1
Jul 2018
→ Nov 2031
Phase 1Current
NCT08652194
2,179 pts·FL
2018-07→2031-11·Not yet recruiting
2,179 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-11-105.6y awayPh2 Data· FL
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P1/2
Not yet…
Catalysts
Ph2 Data
2031-11-10 · 5.6y away
FL
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08652194 | Phase 1/2 | FL | Not yet recr... | 2179 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Zorizanubrutinib | Novo Nordisk | Phase 1 | BTK | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| Pexamavacamten | Daiichi Sankyo | NDA/BLA | TIGIT | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D |